复方鳖甲软肝片与慢肝解郁胶囊治疗肝炎后肝硬化的临床评价

Clinical Evaluation on Fufang Biejia Ruangan Tablets and Mangan Jieyu Capsules for Treating Cirrhosis after Hepatitis

目的:探讨复方鳖甲软肝片与慢肝解郁胶囊治疗肝炎后肝硬化(代偿期)的临床疗效及对生存质量的影响。方法:74例患者随机分为治疗组39例和对照组35例。两组均常规保肝抗病毒治疗,治疗组同时服用复方鳖甲软肝片,4片/次,3次/d,慢肝解郁胶囊,4粒/次,3次/d。两组疗程均为24周。观察临床症状及生存质量,检测透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、IV型胶原(IV-C)。结果:治疗12,24周后治疗组临床症状积分均较对照组低(P<0.01);治疗组HA,LN,PCⅢ及IV-C均低于对照组(P<0.05,P<0.01);治疗组生理领域、心理领域、社会关系领域及总分均明显高于对照组(P<0.05,P<0.01);治疗组有效率87.18%,优于对照的65.71%(P<0.05)。结论:复方鳖甲软肝片与慢肝解郁胶囊治疗肝炎后肝硬化(代偿期),能明显减轻临床症状,改善肝纤维化程度,提高患者生存质量,提高临床疗效。

Objective：To study the clinical curative effect and the influence of the life quality of Fufang Biejia Ruangan tablets （FBRT） and Mangan Jieyu capsules （MJC） for treating cirrhosis after hepatitis （compensatory period）. Method： Seventy-four cases of cirrhosis after hepatitis were randomly divided into the treatment group （n=35） and the control group （n=39）. Two groups were given conventional liver-protecting drugs and antiviral treatment, meanwhile the treatment group was treated by FBRT 4 tablets tid, MJC 4 capsules tid. The course of treatment was 24 weeks. Clinical symptoms, life quality, hyaluronic acid （HA）, laminin （LN）, type Ⅲ procollagen （PC Ⅲ）, type IV collagen （IV-C） were observed and determined. Result： After treatment （12, 24 weeks） clinical symptoms scores in the treatment group were lower than those in control group （P〈0.01）. HA, LN, PC Ⅲ and IV-C in the treatment group were lower than those of the control group （P〈0.05, P〈0.01）. The total scores in physiological, psychological and social aspects in treatment group were significantly higher than those in the control group （P〈0.05, P〈0.01）. The effective rate was 87.18% in the treatment group, and 65.71% in the controls （P〈0.05）. Conclusion： For treating cirrhosis after hepatitis （compensatory period）, FBRT and MJC can obviously relieve clinical symptoms, improve the degree of liver fibrosis, and rise the life quality, increase the efficacy.